Jim Wassil - Aug 1, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Aug 1, 2024
Transactions value $
-$236,527
Form type
4
Date filed
8/5/2024, 04:10 PM
Previous filing
Jul 2, 2024
Next filing
Sep 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Sale -$235K -2.98K -1.41% $78.84 208K Aug 1, 2024 Direct F1, F2
transaction PCVX Common Stock Sale -$1.83K -23 -0.01% $79.47 208K Aug 1, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $78.28 to $79.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.